Skip to Main Content

An off-the-shelf bispecific antibody developed by Roche induced high and durable response rates in patients with a slow-growing type of lymphoma — study results that are likely to secure the treatment’s approval and help it rival a custom-made CAR-T therapy.

The study enrolled 90 patients, all of whom were given intravenous infusions of the Roche drug, called mosunetuzumab. Complete remissions were reported in 54 patients, or 60%, meaning their disease was undetectable. The overall response rate was 80% with median duration of response lasting nearly 23 months.


The enrolled patients were diagnosed with follicular lymphoma, a slow-growing form of non-Hodgkin’s lymphoma. To enter the study, the patients had to have relapsed disease after two or more previous therapies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.